Dr Walkiria Schlindwein

Associate Professor of Pharmaceutics at Leicester School of Pharmacy

Symposium Chair

Walkiria graduated as Chemical Engineer in 1984 (First-class) from the Federal University of Rio de Janeiro, UFRJ, Brazil. She obtained her MSc (Distinction) in Polymer Science and Technology from the Institute of Macromolecules of the UFRJ, Brazil in 1986, PhD in Chemistry from the Department of Chemistry of the University of Leicester, England, in 1990, and DSc in Chemistry from the UFRJ in 1992.

She has over 20 years of experience in academia and is currently Associate Professor of Pharmaceutics at the Leicester School of Pharmacy. Her current research projects are in the areas of pharmaceutical formulations with interest in integrating quality by design in continuous pharmaceutical product development and manufacture. Walkiria is the programme leader of two Postgraduate courses in Pharmaceutical Quality by Design (QbD) and a key member of the academic teaching staff. She oversees all aspects of the distance learning programme including curriculum development, assessment, recruitment and support of students. In addition, she has a strong research interest in the science underpinning QbD and has developed collaborations with numerous organisations that are active in this field. She is member of the Academy for Pharmaceutical Sciences Regulatory Focus Group and of the Continuous Manufacturing and Advanced Crystallisation (CMAC) International Advisory Board.


Professor Dana Brown

Pro Vice-Chancellor/Dean, Faculty of Business and Law
Principal, Leicester Castle Business School

Professor Dana Brown joined De Montfort University (DMU) in March 2016 as the founding Principal of Leicester Castle Business School (LCBS). Raised by her mother in America with her father in England, Dana’s life and career has spanned the two countries and beyond. While completing her BA in Political Science and Slavic Languages at Rutgers University in New Jersey, she spent a year at Exeter University and a further year on Exeter’s Russian language programme in Moscow. After completing her BA, Dana was awarded a Rhodes Scholarship to study for the MPhil in Russian and East European Studies at St. Antony’s College, Oxford University. She later earned her PhD in Political Science from the Massachusetts Institute of Technology (MIT), completing a dissertation on the intersection of market and social reform in former Soviet countries. Dana has worked in and closely with business, starting in high school when she had the opportunity work alongside a former chief executive of F.W. Woolworth during the launch a new start-up retail venture. She was also amongst the first employees of Amazon.com, where she worked as Senior Manager of Operations in the period leading up to the company’s IPO. At MIT, she was part of an initiative of Sloan School of Management that invited executives from the global clothing and footwear industries to participate in emerging discussions about labour issues in global supply chains. She has worked with several companies in executive education and has supervised a number of student entrepreneurship projects, many of which have been launched into successful businesses. Dana is married to Nils and has three young daughters, Petra, Greta and Annika. Her family provides her with inspiration and support in everything she does.


Dr Line Lundsberg

Global Technology Partner, Regulatory & GMP I Quality by Design I Control Strategy I PAT I QRM

Line works for NNE as a Global Technology Partner in GMP and Regulatory aspects. She has been working in the pharmaceutical Industry, both in pharmaceutical development and product manufacturing for the last 20 years. Her background is in physics and I hold a PhD in Process Analytical Technology. Her main consulting areas are Regulatory Expectations, Future pharma trends in smart manufacturing & control, Quality by Design (QbD), Process Analytical Technology including Real Time Release Testing, Process Validation, and Good Manufacturing Principles combined with science and risk based innovative development and manufacturing. She was one of the pioneers that together with the FDA, EMA and the ASTM standard organisation took part in developing the Science and Risk based framework that today is the new foundation for product development and manufacturing in the pharmaceutical and biotech industry.


Dr Indra Joshi

Digital Health and AI Clinical Lead (NHS England)

Indra is an emergency medicine doctor who is the clinical lead for NHS England’s Empower the Person Portfolio, which aims to create a citizen-friendly digital interface for the NHS. She admits that the NHS is having to play catch-up in parts with the digital world, but says creating a digital NHS service that is fully inclusive, and that citizens trust, takes time. Her role is to empower patients and citizens to improve their own experience of the NHS, and taking care of their own health


Professor Kendall Pitt

Senior  Technical Director in Global Manufacturing and Supply for GlaxoSmithKline

Kendal Pitt, Ph.D (London University), B.Pharm (University of Nottingham), is a Senior  Technical Director in Global Manufacturing and Supply for GlaxoSmithKline based at Ware, UK.  He is a Fellow of the Royal Pharmaceutical Society (FRPharmS) and a Fellow of the Academy of Pharmaceutical Sciences (FAPS). Kendal has worked in the Pharmaceutical Industry for over 30 years, with Wellcome Foundation Ltd., Roche Pharmaceuticals and more recently for Merck.  He has headed groups in both the United States and Great Britain and has led project teams responsible for the successful filing and launch of both tablets and freeze-dried oral dosage forms.   Primary research interests are in powder compaction, powder flow and granulation process optimisation, including the use of compaction simulators in tablet and capsule product development.  He has additionally published in the areas of formulation and design for nasal delivery of pharmaceuticals and on statistical design of experiments, and has co-authored chapters on formulation, tabletting and on strength testing.


Professor Melissa Hanna-Brown

Associate Research Fellow, Pfizer UK


Professor Hanna-Brown is based at Pfizer’s UK research centre in Sandwich, Kent and is  part of Pfizer’s Technology & Innovation team. She and her colleagues work closely with external organisations to bring the best technologies and organisations together to accelerate medicines development timelines. She is also playing an active role in promoting gender parity and Diversity & Inclusion (D&I) at her company. Writing in Pfizer’s 2018 Gender Pay Gap Report, Professor Hanna-Brown commented: “To sustain and promote our inclusive culture, we need everyone to play a part. We want to see every UK colleague setting a D&I goal in 2018. This will help us collectively achieve a level playing field for all colleagues. It’s the right thing to do socially, morally and for the success  of our company.”


Dr Andrea Johnston

CMAC EPSRC Centre Manager

A solid-state chemist with expertise in the area of crystallisation and physical form screening in terms of identifying new polymorphs, solvates or co-crystals and performing full physical analyses of crystalline forms. Andrea also has a keen interest in the use of chemoinformatics in both rationalising experiments for physical form screening and determining which parameters are governing crystalline outcome. Responsible for planning and implementation of Centre activities; outreach; Centre / DTC finance. mages Centre / DTC staff.


Dr Alastair Coupe

Senior Director, Drug Product Design, Pharmaceutical Sciences, Pfizer Ltd, Sandwich UK

Alastair joined Pfizer in 1995 and over the past 20 years has worked on a wide range of drug products (e.g Tikosyn, Vfend, Sutent, Macugen, Celzentry, Toviaz and Bosulif) and drug delivery technologies (Vfend IV, Caduet, Norvasc ODT and Viagra ODT) including IR and MR tablets and capsules, parenteral and oral liquid products and inhalation dosage forms.  In addition, he has presented CMC packages at EMEA, FDA and PMDA (Japan).  Alastair is currently responsible for Formulation and Process Development in Sandwich.  As a leader, he has run groups ranging from 2 to 150+ including GMP Clinical Supplies manufacturing, paediatric and inhalation development.  Alastair is currently leading the Innovate UK cross industry/academia collaborative R&D project “Accelerating paediatric development through smart design and predictive science”.  He is also a Management Board member for the University of Nottingham/UCL CDT in Advanced and Targeted Therapeutics and a member of the Academy for Pharmaceutical Sciences Regulatory Focus Group Steering Committee. He received a B.Pharm. (1st Class) in Pharmacy (1987) and a Ph.D in Drug Delivery (Nottingham University, 1991).


Dr Helen Muirhead

Senior Vice President Respiratory Medicines at GMPharma Limited

Helen now is an independent Respiratory Medicine Expert, acting as a consultant after 30 years with GSK in both R&D and Manufacturing. Helen is also now involved in teaching at Universities and supports Lung Disease charities. In GSK, Helen headed up the Respiratory Centre of Excellence during the late stages of Product Development through Regulatory Filing and Commercial Launch and supply of new Medicines – in the Ellipta Portfolio (Including the recent Trelegy, triple drug therapy). Helen was also responsible for the classic and establish brands; the existing Diskus Portfolio (Including Advair).


Professor Mike Hannay

Managing Director East Midlands Academic health Science Network (EMAHSN) and Chair of the AHSN Network

Mike has more than 25 years’ experience of working in the pharmaceutical industry, with an excellent track record of building collaboration with healthcare and academia. He joined EMAHSN in July 2016 from ThermoFisher Scientific, where he had worked since 2013 as Vice President for the UK BioPharma Services Division. That role built upon his significant experience both nationally and internationally, including Vice President of Medicines Development at AstraZeneca. In his role with EMAHSN, Mike leads the organisation in helping to address some of the biggest health challenges facing the region. Mike is currently Chair of the National AHSN Network, a collaboration of England’s 15 AHSNs.


Professor Gordon Muirhead

President of GMPharma Limited, a Pharmaceutical Consultancy

He is a Pharmacist and has worked in the Pharmaceutical Industry – in senior Manufacturing, Operations, General Management and Development global roles – for over 30 years and is a Fellow of the Royal Pharmaceutical Society (FRPharmS).

Previously, Gordon was Vice President of Global New Medicines Introduction within the Global Manufacturing  and Supply division of GlaxoSmithKline (GSK) for 12 years. In this time GSK Filed, Launched and Transfered a significant number of new medicines, new combination medicines, and new drug-device combinations… from multiple sites. Prior to this role, he was Head of Global Process Technologies within Product Development, R&D, GSK to advance Process Analytical Technologies (PAT), Quality by Design (QbD) and Secondary Continuous Processing within that company. Gordon was one of the first Senior Fellows in GSK Manufacturing and is now the first GSK Emeritus Senior Fellow. Gordon is also Visiting Professor of Pharmaceutics within the Leicester School of Pharmacy at De Montfort University with a particular research interest into the practical application of a Rapid Adaptive Continuous development and commercial manufacturing platform, underpinned by QbD and PAT. Described as “an Engineer, trapped in the body of a Pharmacist”… Gordon is also an Associate Fellow of the Institute of Chemical Engineers (AFIChemE). He is also active in STEM initiatives, to help inspire the next generations of engineers and scientists. He is the proud grandfather of two grand-daughters; Abbie (13) and Lily (9), and learns from them both… all the time. An ex-professional musician, Gordon still believes he can become a famous Rock Star and has a Recording Studio and a bank of guitars ready for that big break!